About Us
From 20 years of scientific observations of metabolic change as a result of salt intake, came the discovery by Dr Karen Duggan in 2003 that a naturally occurring molecule in the human body was capable of reversing fibrosis caused by hypertension and other chronic diseases such as diabetes.
In 2005 Vectus Biosystems Limited was formed to take Dr Duggan’s discovery through to an orally deliverable drug.
Today, Vectus Biosystems Limited holds patents around the Vasoactive Intestinal Peptide (VIP) and its fragments as a therapeutic candidate to treat cardiovascular fibrosis and systolic blood pressure.
Vectus Biosystems Limited intends to remain a research and development company, and license its current and future technologies.